COLLEGE TER BEOORDELING VAN GENEESMIDDELEN

Public Assessment Report

Scientific discussion

Ibuprofen Patheon Express mini 200 mg, soft capsules (ibuprofen)

NL/H/5369/001/DC

Date: 26 September 2024

This module reflects the scientific discussion for the non-approval of Ibuprofen Patheon Express mini 200 mg, soft capsules. The procedure was finalised on 23 November 2022.

I. INTRODUCTION

Based on the review of the quality, safety and efficacy data, the Member States have refused a marketing authorisation for Ibuprofen Patheon Express mini 200 mg, soft capsules, from Patheon Softgels B.V.

The indication applied for was:
This medical product is indicated in adults and adolescents weighing from 40 kg (12 years of age and above) for the short-term symptomatic treatment of mild to moderate pain such as headache, period pain, dental pain and fever and pain associated with the common cold.

The marketing authorisation was applied for pursuant to Article 10(1), generic of Directive 2001/83/EC, claiming essential similarity between the new product and the European Reference Product (ERP) Nurofen 200 mg Rapid Relief capsules (MA# PA0979/032/012) which was initially registered in Ireland by Reckitt Benckiser Ireland Ltd. Since 24 July 2009. The justification to use this reference is based on information received from Ireland, this was circulated during the validation period.

The concerned member states (CMS) involved in this procedure were Croatia, Ireland, Portugal and Spain.

General comments on the application
For this application, a bioequivalence study has been performed between Nurofen Fastine Zavance 400 mg, soft capsules (NL/H/5368/002/DC) and Nurofen Express 400 mg soft capsules (NL/H/4313/001, Reckitt Benckiser Healthcare, BG) as reference product. For Ibuprofen Patheon Express mini 200 mg, a biowaiver has been requested.

The application was discussed in the board meeting of 20 October 2022. Furthermore, a breakout session (BOS) was held in November 2022.

II. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

The marketing authorisation could not be granted due to major objections qualifying as potential serious risk to public health as defined in the Guideline on the definition of a potential serious risk to public health in the context of Article 29(1) and (2) of Directive 2001/83/EC — March 2006 (2006/C 133/05):

Overall benefit-risk

From a chemical/pharmacokinetic point of view, a marketing authorisation for the product Ibuprofen Patheon Express mini 200 mg could not be granted.

A bioequivalence study has been performed for Nurofen Fastine Zavance 400 mg, soft capsules with the corresponding reference product strength Nurofen Express 400 mg soft capsules. The MAH claimed that the results of this bioequivalence study are applicable to the reference product Nurofen 200 mg Rapid Relief used for this application and requested a biowaiver for Ibuprofen Patheon Express mini 200 mg. To complement the bioequivalence study and to support the biowaiver, comparative dissolution studies were conducted at pH 1.2, 4.5, pH 6.8 and 7.2.

Bioequivalence with the reference has been demonstrated for the 400 mg strength. It has also been demonstrated that the outcome of the bioequivalence study with Nurofen Express 400 mg soft capsules is also representative for showing bioequivalence of the reference Nurofen 200 mg Rapid Relief with the 200 mg test product. However, the similarity of the dissolution profiles of Ibuprofen Patheon Express mini 200 mg and Nurofen Fastine Zavance 400 mg at pH 6.8 could not be demonstrated. The conventional f_2 calculations applied by the MAH and the conclusion that similarity has been demonstrated are considered inaccurate; as the f_2 criteria were not met, f_2 cannot not be calculated.

Since similarity between the dissolution profiles of the 400 mg and 200 mg strengths was not demonstrated, the results of the bioequivalence study with the 400 mg strength cannot be extrapolated to the 200 mg strength according to the conditions in the Guideline on the Investigation of Bioequivalence CPMP/EWP/QWP/1401/98 Rev. 1/Corr*, section 4.1.6. Overall, the biowaiver was not approved and the bioequivalence of the 200 mg strength with the reference has not been proven.

Therefore, the Board concluded that the marketing authorisation for Ibuprofen Patheon Express mini 200 mg, soft capsules cannot be granted. Agreement on this conclusion was reached with the concerned member states. The decentralised procedure was finalised with a negative outcome on 23 November 2022.